open access

Vol 63, No 6 (2012)
Original papers
Published online: 2013-01-02
Submitted: 2013-02-15
Get Citation

Genetic predispositions and the short- and long-term effects of hormonal therapy on bone mineral density in girls with functional hypothalamic amenorrhoea

Elżbieta Sowińska-Przepiera, Kornel Chełstowski, Zbigniew Friebe, Anhelli Syrenicz
Endokrynologia Polska 2012;63(6):420-426.

open access

Vol 63, No 6 (2012)
Original papers
Published online: 2013-01-02
Submitted: 2013-02-15

Abstract


Introduction: The aim of this study was to verify if genetic factors influence the short- and long-term therapeutic responses to oestroprogestagen (OP) therapy, implemented in girls with functional hypothalamic amenorrhoea (FHA) in order to improve their bone mineral density (BMD).
Material and methods: The study included 78 FHA girls who underwent a four-year sequential OP therapy with 17-beta oestradiol and didrogesterone. Changes in the lumbar spine BMD were determined at the end of the therapy and six years after its discontinuation, and analysed in regards to PvuII and XbaI polymorphisms of oestrogen receptor-alpha gene, BsmI polymorphism of vitamin D3 receptor gene, and Sp1 polymorphism of the type-1 collagen gene.
Results: After four years of OP therapy, a significant increase in BMD was documented in the studied group. Follow-up densitometry performed six years after completing the therapy revealed a significant decrease in BMD level; nonetheless, the values of this parameter were still significantly higher compared to pretreatment level. Neither the particular polymorphisms nor their combinations influenced the relative change in BMD at the end of the therapy and after a six-year follow-up.
Conclusions: Variability of genes involved in oestrogen, vitamin D3 and collagen metabolism does not influence the short- and long-term results of OP therapy in girls with FHA. (Endokrynol Pol 2012; 63 (6): 420–426)

Abstract


Introduction: The aim of this study was to verify if genetic factors influence the short- and long-term therapeutic responses to oestroprogestagen (OP) therapy, implemented in girls with functional hypothalamic amenorrhoea (FHA) in order to improve their bone mineral density (BMD).
Material and methods: The study included 78 FHA girls who underwent a four-year sequential OP therapy with 17-beta oestradiol and didrogesterone. Changes in the lumbar spine BMD were determined at the end of the therapy and six years after its discontinuation, and analysed in regards to PvuII and XbaI polymorphisms of oestrogen receptor-alpha gene, BsmI polymorphism of vitamin D3 receptor gene, and Sp1 polymorphism of the type-1 collagen gene.
Results: After four years of OP therapy, a significant increase in BMD was documented in the studied group. Follow-up densitometry performed six years after completing the therapy revealed a significant decrease in BMD level; nonetheless, the values of this parameter were still significantly higher compared to pretreatment level. Neither the particular polymorphisms nor their combinations influenced the relative change in BMD at the end of the therapy and after a six-year follow-up.
Conclusions: Variability of genes involved in oestrogen, vitamin D3 and collagen metabolism does not influence the short- and long-term results of OP therapy in girls with FHA. (Endokrynol Pol 2012; 63 (6): 420–426)
Get Citation

Keywords

bone mineral density; functional hypothalamic amenorrhoea; hormone replacement therapy; osteoporosis

About this article
Title

Genetic predispositions and the short- and long-term effects of hormonal therapy on bone mineral density in girls with functional hypothalamic amenorrhoea

Journal

Endokrynologia Polska

Issue

Vol 63, No 6 (2012)

Pages

420-426

Published online

2013-01-02

Bibliographic record

Endokrynologia Polska 2012;63(6):420-426.

Keywords

bone mineral density
functional hypothalamic amenorrhoea
hormone replacement therapy
osteoporosis

Authors

Elżbieta Sowińska-Przepiera
Kornel Chełstowski
Zbigniew Friebe
Anhelli Syrenicz

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl